Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526988 · ClinicalTrials.gov registry record · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
A NA study of Heart Failure With Reduced Ejection Fraction, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 2,200
- Enrollment target
- 5
- Study locations
NCT06526988: Recruiting NA study of Heart Failure With Reduced Ejection Fraction, sponsored by University of Colorado, Denver.
NCT06526988 is a NA study of Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 2,200 participants, below the 3,884-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (43% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526988, a NA study of Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,200 participants
- Enrollment target
- 5
- Study locations
Study Summary
An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of life, and survival.1,2 However, GDMT underuse occurs for the vast majority of patients with HFrEF. Two recent trials demonstrated improved GDMT prescribing during a clinic visit, each using automated delivery of a patient-centered decision support tool to promote a proactive and holistic approach to prescribing: EPIC-HF (NCT03334188) tested a brief video and checklist document sent to patients just prior to a clinic visit encouraging them to work with their clinicians to make at least 1 positive change to their GDMT; PROMPT-HF (NCT05433220) tested tailored electronic health record (EHR) alerts for GDMT intensification delivered to clinicians during clinic visits. The current I-I-CAPTAIN-HF study aims to broadly implement and test the EPIC-HF patient-facing and PROMPT-HF clinician-facing tools for HFrEF medication intensification at 5 health systems around the country through a pragmatic cluster-randomized implementation-effectiveness trial. This will occur through an initial phase of adaptation of the 2 tools at each health system. Once ready, the 2 tools will be tested using a 2x2 randomization at the clinician-level. In parallel, formal assessment of the implementation of EPIC-HF and PROMPT-HF will work to understand the most effective means of intervention design and delivery, as well as adaptations due to contextual factors to optimize use.
Primary Outcome
The primary outcome for this trial is the proportion of patients with HFrEF who have an increase in the number of prescribed HFrEF therapies (beta blockers, ACE-I/ARB/ARNI, MRA, SGLT2i) and/or dosing intensification from pre-clinic visit to 1 day after.
Conditions Studied
Interventions
- BEHAVIORAL EPIC-HF Patient-facing Tool
- BEHAVIORAL PROMPT-HF Clinician-facing Alert
Study Locations (5)
California
- Sutter Health - Walnut Creek
Colorado
- University of Colorado - Aurora
Connecticut
- Yale University - New Haven
Illinois
- Northwestern University - Chicago
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2028-09-01 |
| Phase | NA |
What NCT06526988 shows while recruiting
NCT06526988 is an interventional study that assigns participants to a tested intervention. Its 2,200 participants enrollment target places it among the larger protocols in the corpus, below the 3,884-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which EPIC-HF Patient-facing Tool is the first listed.
NCT06526988 lists 5 locations in 5 states (California, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06526988 about?
NCT06526988 is a clinical study titled "Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure". An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of li...
What is the current status of trial NCT06526988?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,200 participants. The study started on 2025-03-06. Estimated completion is 2028-09-01.
What conditions does trial NCT06526988 study?
This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT06526988?
The interventions under investigation include: EPIC-HF Patient-facing Tool (BEHAVIORAL), PROMPT-HF Clinician-facing Alert (BEHAVIORAL).
Who is sponsoring clinical trial NCT06526988?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526988 being conducted?
This trial has 5 study locations across California, Colorado, Connecticut, Illinois, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Reduced Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06526988's enrollment target sits among peer trials
2,200 8th of 27 higher than 20 of 27 other Heart Failure With Reduced Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Reduced Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction
RECRUITING · NA
-
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
RECRUITING · NA
-
Home-Based Cardiac Rehabilitation for Patients With Heart Failure
RECRUITING · NA
-
The CardioClip Study
RECRUITING · NA
-
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
- NCT06828406 · 2,200 participants · NA
Improving Safety, Patient Experience and Equity Through Shared Decision-making Huddles in Labor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI